Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)

Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Groth, Marie, Winkelmann, Veronika Eva, Bopp, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459882/
https://www.ncbi.nlm.nih.gov/pubmed/37631942
http://dx.doi.org/10.3390/vaccines11081374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459882/
https://www.ncbi.nlm.nih.gov/pubmed/37631942
http://dx.doi.org/10.3390/vaccines11081374

Ejemplares similares